Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China

Oct 15, 2019 21:24 JST

Source: Eisai

TOKYO, Oct 15, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that Eisai received a New Drug Approval for its in-house discovered and developed antiepileptic drug (AED) Fycompa (perampanel) from the China National Medical Products Administration (NMPA) for use in an adjunctive treatment of partial onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older. Fycompa was designated for Priority Review by the NMPA due to its significant clinical benefits compared to existing treatments, and was approved in about 12 months since the submission in September 2018.

In China, it is estimated that there are approximately 9 million patients with epilepsy, approximately 60% of whom being affected by partial-onset seizures. About 40% patients with partial-onset seizures require adjunctive treatment.1 As approximately 30% of patients with epilepsy are unable to control their seizures with currently available AEDs,2 this is a disease with significant unmet medical needs.

Fycompa is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. Administered orally once-daily, it is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes.

Fycompa has been approved in over 60 countries around the world as an adjunctive treatment for partial- onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older. In addition, Fycompa has been approved in over 55 countries as an adjunctive treatment for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. In the United States, Fycompa is also indicated for monotherapy and adjunctive use in the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older.

Eisai considers neurology including epilepsy, a therapeutic area of focus. With this approval of Fycompa in China, Eisai pursues our mission to provide "seizure freedom" to a greater number of patients with epilepsy across the world living. Eisai seeks to address the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.

About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:

Eisai Co., Ltd. 
Public Relations Department
+81-(0)3-3817-5120

Source: Eisai
Sectors: HealthCare

Related Press Release

Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease

July 14 2020 08:20 JST

Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded

July 13 2020 10:47 JST

Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease

July 09 2020 11:20 JST

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

July 09 2020 11:11 JST

Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong

July 08 2020 13:33 JST

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tazemetostat for EZH2 Gene Mutation-Positive Follicular Lymphoma

July 08 2020 13:16 JST

Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan

July 06 2020 08:33 JST

Eisai: New Fine Granule Formulation of Anti-epileptic Drug Fycompa Launched in Japan

July 06 2020 08:05 JST

Remap-Cap to Partner With Eisai on Innovative Trial to Combat COVID

July 01 2020 13:02 JST

Eisai Receives Approval for Parkinson's Disease Treatment Equfina in South Korea

June 25 2020 10:47 JST

More Press release >>

Latest Press Release

MITSUBISHI MOTORS Launches the All-New Crossover XPANDER CROSS in Vietnam

Jul 16, 2020 10:52 JST

NEC Provides Secure Document Management and Sharing Service "Obbligato/Collaboration Platform" in China
Jul 16, 2020 10:34 JST

Hitachi ABB Power Grids Launches Game-changing EV Charging System for Large-scale e-Mobility
Jul 15, 2020 20:05 JST

Hitachi Kicks Off "Hitachi Origin Story" Website

Jul 15, 2020 17:14 JST

SDK Develops Wet-Resistant Heat-Conductive Aluminum Nitride Filler

Jul 14, 2020 17:00 JST

Mitsubishi Coporation: Initiation of "Technology Development for Para-xylene Production from CO2"
Jul 14, 2020 09:51 JST

Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease
Jul 14, 2020 09:20 JST

CATL and Honda Sign Agreement to Form Comprehensive Strategic Alliance on Batteries for New Energy Vehicles
Jul 13, 2020 12:48 JST

Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded
Jul 13, 2020 11:47 JST

Fujitsu Develops World's First AI technology to Accurately Capture Characteristics of High-Dimensional Data Without Labeled Training Data

Jul 13, 2020 10:12 JST

TOYOTA GAZOO Racing WRC Challenge Program

Jul 10, 2020 17:22 JST

Hitachi ABB Power Grids India Wins INR 120 Crore Order for Indian Railways Electrification
Jul 10, 2020 09:07 JST

NEC Solution Innovators Establishes "FonesLife," a healthcare business company that contributes to extending healthy life expectancy
Jul 09, 2020 14:34 JST

Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease
Jul 09, 2020 12:20 JST

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Jul 09, 2020 12:11 JST

"Corolla Meets SUV"--Toyota Unveils Corolla Cross in Thailand, The New Compact SUV with Strength and Functionality to the Corolla Series

Jul 09, 2020 10:59 JST

Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong
Jul 08, 2020 14:33 JST

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tazemetostat for EZH2 Gene Mutation-Positive Follicular Lymphoma
Jul 08, 2020 14:16 JST

HSPP Announces Corporate Name Change to Honda India Power Products Limited
Jul 07, 2020 14:37 JST

Lexus Premieres New LS

Jul 07, 2020 13:31 JST

More Latest Release >>